Gabapentin Capsule
Product Images NDC 63629-7306

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 63629-7306). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Gabapentin Capsules Usp 1)

A formula showing the creatinine clearance calculation used in clinical settings, involving age, weight, and serum creatinine levels. This is not product-specific but appears to represent a pharmacokinetic or dosing-related formula relevant for drugs like Gabapentin.*

FDA Label Image

Chem Structure (Gabapentin Capsules Usp 2)

Chemical structure of gabapentin, showing its cyclohexane ring attached to an amino group and a carboxylic acid group.*

FDA Label Image

10 (Gabapentin Capsules Usp 3)

Line graph depicting mean pain score over an 8-week period comparing placebo and Gabapentin 3600 mg/day. The x-axis represents weeks from baseline to week 8, and the y-axis indicates mean pain scores ranging from 0 to 10. The graph shows a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

10 (Gabapentin Capsules Usp 4)

A line graph displaying mean pain scores over seven weeks, comparing placebo with gabapentin dosages of 1800 mg/day and 2400 mg/day. The x-axis shows weeks including baseline, and the y-axis shows mean pain scores from 0 to 10. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

10 (Gabapentin Capsules Usp 5)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies.' It compares the proportion of responders between placebo (PBO) and Gabapentin (GBP) at different doses in two studies. Study 1 shows 12% for placebo and 29% for Gabapentin 3600 mg. Study 2 shows 14% for placebo, 32% for Gabapentin 1800 mg, and 34% for Gabapentin 2400 mg. Statistical significance markers are included.*

FDA Label Image

Figure 4 (Gabapentin Capsules Usp 6)

A scatter plot comparing the percentage difference at various daily doses (600 mg to 1800 mg) of gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose in mg and the y-axis shows difference in percentage. Study a is shown with black squares, study b with gray squares, and study c with white squares.*

FDA Label Image

Label Image (Lbl636297306)

Gabapentin 300 mg (CV) capsule label from Bryant Ranch Prepack. The label indicates the capsule is yellow (IP 102) and provides storage instructions at 20°-25°C (68°-77°F). It contains a warning about possible dizziness and advises keeping all drugs out of reach of children. The package compares to Neurontin 300 mg (CV) capsule by Amneal Pharmaceuticals Pvt. Ltd., and shows an NDC of 63629-7306-1 with a quantity of 90 capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.